Form 4: CEO Christopher Gibson Sells 100,000 RXRX Shares

Recursion Pharmaceuticals CEO Christopher Gibson executed a planned sale of 100,000 Class A Common Stock shares at $4.84 per share.

Summary

• Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals, Inc. (RXRX), reported transactions involving the company's securities.
• On August 26, 2025, Gibson converted 100,000 shares of Class B Common Stock into Class A Common Stock.
• Immediately following the conversion, he sold 100,000 shares of Class A Common Stock at a price of $4.84 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Gibson on May 12, 2025.
• Following these reported transactions, Gibson directly holds 954,229 shares of Class A Common Stock.
• He also directly holds 5,373,034 shares of Class B Common Stock, which are convertible into Class A Common Stock on a one-for-one basis and have no expiration date.
• Indirect beneficial ownership includes 386,000 shares of Class B Common Stock held by LAHWRAN-3 LLC, 50,000 shares by the Gibson Family Trust, and 388,000 shares by LAHWRAN-4 LLC.
• Gibson holds various stock options (Right to Buy) with exercise prices ranging from $2.48 to $11.40, and expiration dates extending up to February 3, 2035. These options have different vesting schedules, typically vesting monthly over 48 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sale is pre-planned under a 10b5-1 plan, which mitigates the negative signal, it still represents a reduction in direct insider ownership. The sale price of $4.84 is a data point for the stock's valuation at the time of the transaction, but the filing itself does not provide new operational or financial performance data.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event for personal financial management rather than an immediate reaction to new, potentially negative, company information.

Negatives

• A significant sale of 100,000 shares by the CEO, even if planned, could be perceived negatively by some investors as it reduces direct insider ownership and may lead to questions about management's long-term conviction, despite the 10b5-1 plan.

Risks

• Potential for negative investor sentiment due to insider selling, which could exert downward pressure on the company's stock price.
• The market may interpret the sale as a signal, regardless of the 10b5-1 plan, potentially affecting investor confidence.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide specific industry context or competitive analysis. Insider sales, even under a 10b5-1 plan, are common for executives managing personal finances and diversifying portfolios, particularly in high-growth sectors like biotechnology where Recursion Pharmaceuticals operates.

Related Party Transactions

• Indirect beneficial ownership of Class B Common Stock through LAHWRAN-3 LLC, where the Reporting Person is a member and manager.
• Indirect beneficial ownership of Class B Common Stock through the Gibson Family Trust, where the Reporting Person serves as Trustee.
• Indirect beneficial ownership of Class B Common Stock through LAHWRAN-4 LLC, where the Reporting Person is a member and manager.

Stakeholder Impact

• **Shareholders:** May interpret the CEO's sale as a signal, potentially influencing their investment decisions. The pre-planned nature (10b5-1) can mitigate concerns about the timing of the sale.
• **Employees:** No direct impact on employees is indicated by this filing.
• **Customers/Suppliers/Creditors:** No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Continued vesting of various stock options held by Christopher Gibson according to their respective schedules, with monthly vesting typically occurring over 48 months for options with exercise prices of $7.25, $10.09, $8.55, $11.40, and $2.48.

Key Dates

Recommendation

The filing reports a planned insider sale by the CEO under a Rule 10b5-1 plan. While insider selling can sometimes be a negative signal, the pre-arranged nature suggests it's for personal financial management rather than a reaction to adverse company news. Without additional company-specific financial or operational updates, this transaction alone does not warrant a 'buy' or 'sell' recommendation, but rather a 'hold' as investors should monitor future company performance and broader market conditions.

Keywords

Recursion Pharmaceuticals, RXRX, Christopher Gibson, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Class A Common Stock, Class B Common Stock, Stock Options